Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

EU approves drug for treating and preventing DVT and PE

  • Comment

A new drug for preventing and treating both deep vein thrombosis and pulmonary embolism has been approved.

The European Commission has today approved apixaban (Eliquis) for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults.

The European Commission approval applies to all European Union member states, as well as Iceland and Norway.

It broadens the clinical use for apixaban, which is already approved for the prevention of venous thromboembolism in adults who have undergone elective total hip or knee replacement surgery, and the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.

The drug has been jointly developed by Bristol-Myers Squibb and Pfizer. 

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs